Skip to main content
    V

    Vericel Corp Ord (VCEL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $57.48
    +0.52 (+0.91%)

    Market Cap: $2.91B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Vericel Corp Ord (VCEL) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Vericel Corp Ord (VCEL) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Vericel Corp Ord reported EPS of $0.27. It beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    55%(21/38)
    Avg Surprise
    +34.67%
    Streak
    2 Q

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.58
    Range$0.46 - $0.65
    10 analysts
    Revenue Consensus
    $116.31M
    Range$110.91M - $120.33M
    10 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.03
    Range-$0.09 - $0.02
    5 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.06+55.2%
    60d ago-$0.06+55.2%
    30d ago-$0.06+55.2%
    7d ago-$0.06+55.2%
    Current-$0.03
    Revenue Consensus
    $80.31M
    Range$74.30M - $84.10M
    7 analysts

    Next Report

    VCEL has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 28.9% above the $0.45 reported for the quarter ended Dec 31, 2025.

    VCEL Earnings Call

    The latest VCEL earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 38 quarters below that had an estimate, VCEL beat 21, missed 12 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $85.37M, up 26.5% from $67.50M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.27$0.02$0.02 - $0.10N/AN/A+170.0%51 up, 0 downNov 5, 2026$85.37M
    Jun 30, 2026$0.04-$0.04-$0.06 - $0.00+200.00%BeatN/A60 up, 0 downJul 30, 2026$77.46M
    Mar 31, 2026-$0.12-$0.16-$0.17 - -$0.14+25.00%BeatN/A60 up, 1 downMay 7, 2026$68.42M
    Dec 31, 2025$0.45$0.45$0.31 - $0.520.00%In line+18.4%51 up, 2 downFeb 26, 2026$92.92M
    Sep 30, 2025$0.10-$0.01-$0.09 - $0.03N/AN/AN/A60 up, 3 downNov 6, 2025$67.50M
    Jun 30, 2025-$0.01-$0.04-$0.08 - -$0.01+75.00%BeatN/A61 up, 1 downJul 31, 2025$63.24M
    Mar 31, 2025-$0.23-$0.15-$0.25 - -$0.06-53.33%MissN/A61 up, 1 downMay 8, 2025$52.60M
    Dec 31, 2024$0.38$0.34$0.33 - $0.35+11.76%Beat+46.2%20 up, 1 downFeb 27, 2025$75.38M
    Sep 30, 2024-$0.02-$0.05-$0.08 - -$0.02+60.00%BeatN/A70 up, 0 downNov 7, 2024$57.91M
    Jun 30, 2024-$0.10-$0.09-$0.15 - -$0.05-11.11%MissN/A60 up, 0 downAug 1, 2024$52.66M
    Mar 31, 2024-$0.08-$0.10-$0.17 - -$0.05+20.00%BeatN/A60 up, 0 downMay 8, 2024$51.28M
    Dec 31, 2023$0.26$0.17$0.14 - $0.20+52.94%Beat+116.7%61 up, 0 downFeb 29, 2024$65.00M
    Sep 30, 2023-$0.05-$0.12-$0.14 - -$0.09+58.33%BeatN/A60 up, 0 downNov 8, 2023$45.58M
    Jun 30, 2023-$0.11-$0.15-$0.18 - -$0.11+26.67%BeatN/A50 up, 0 downAug 2, 2023$45.92M
    Mar 31, 2023-$0.16-$0.16-$0.18 - -$0.130.00%In lineN/A50 up, 0 downMay 10, 2023$41.02M
    Dec 31, 2022$0.12$0.04-$0.01 - $0.08+200.00%Beat+33.3%50 up, 0 downFeb 23, 2023$52.69M
    Sep 30, 2022-$0.14-$0.10-$0.13 - -$0.04-40.00%MissN/A50 up, 0 downNov 9, 2022$38.55M
    Jun 30, 2022-$0.19-$0.12-$0.14 - -$0.09-58.33%MissN/A50 up, 0 downAug 3, 2022$37.05M
    Mar 31, 2022-$0.15-$0.12-$0.31 - -$0.02-25.00%MissN/A60 up, 0 downMay 4, 2022$36.07M
    Dec 31, 2021$0.09$0.14$0.06 - $0.19-35.71%Miss-64.0%60 up, 0 downFeb 24, 2022$47.59M
    Sep 30, 2021-$0.11-$0.02-$0.05 - $0.01-450.00%Miss-237.5%81 up, 0 downNov 9, 2021$34.51M
    Jun 30, 2021-$0.08-$0.09-$0.14 - -$0.03+11.11%BeatN/A8N/AAug 4, 2021$39.52M
    Mar 31, 2021-$0.07-$0.04-$0.10 - $0.00-75.00%MissN/A8N/AMay 5, 2021$34.57M
    Dec 31, 2020$0.25$0.20$0.17 - $0.25+25.00%Beat+25.0%8N/AFeb 24, 2021$45.23M
    Sep 30, 2020$0.08-$0.02-$0.09 - $0.10+500.00%Beat+14.3%7N/ANov 5, 2020$32.26M
    Jun 30, 2020-$0.18-$0.20-$0.26 - -$0.15+10.00%BeatN/A6N/AAug 5, 2020$20.01M
    Mar 31, 2020-$0.10-$0.08-$0.12 - -$0.05-25.00%MissN/A6N/AMay 5, 2020$26.68M
    Dec 31, 2019$0.20$0.20$0.17 - $0.230.00%In line+53.8%6N/AFeb 25, 2020$39.39M
    Sep 30, 2019$0.07-$0.02-$0.04 - $0.01+450.00%BeatN/A6N/ANov 5, 2019$30.50M
    Jun 30, 2019-$0.05-$0.06N/A+16.67%BeatN/A4N/AAug 6, 2019$26.15M
    Mar 31, 2019-$0.07-$0.07-$0.10 - -$0.020.00%In lineN/A5N/AMay 7, 2019$21.81M
    Dec 31, 2018$0.13$0.04$0.03 - $0.05+225.00%Beat+333.3%5N/AFeb 26, 2019$31.34M
    Sep 30, 2018-$0.02-$0.11-$0.13 - -$0.08+81.82%BeatN/A5N/ANov 6, 2018$22.48M
    Jun 30, 2018-$0.12-$0.12-$0.13 - -$0.090.00%In lineN/A5N/AAug 6, 2018$19.01M
    Mar 31, 2018-$0.21-$0.13-$0.16 - -$0.11-61.54%MissN/A5N/AMay 8, 2018$18.03M
    Dec 31, 2017$0.03-$0.07-$0.10 - -$0.04+142.86%BeatN/A4N/AMar 5, 2018$23.35M
    Sep 30, 2017-$0.13-$0.16N/A+18.75%BeatN/AN/AN/ANov 7, 2017$14.26M
    Jun 30, 2017-$0.07-$0.19N/A+63.16%BeatN/AN/AN/AAug 9, 2017$16.95M
    Mar 31, 2017-$0.31-$0.16N/A-93.75%MissN/AN/AN/AMay 10, 2017$9.36M
    Dec 31, 2016-$0.23-$0.18N/A-27.78%MissN/AN/AN/AMar 10, 2017$16.52M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.31, up 72.2% from the year before. It was -$0.79 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.31+72.2%
    Dec 31, 2024$0.18N/A
    Dec 31, 2023-$0.06N/A
    Dec 31, 2022-$0.36N/A
    Dec 31, 2021-$0.17-440.0%
    Dec 31, 2020$0.05-66.7%
    Dec 31, 2019$0.15N/A
    Dec 31, 2018-$0.22N/A
    Dec 31, 2017-$0.48N/A
    Dec 31, 2016-$0.79N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,900 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,86312
    2026Q1Mar 31, 20267,63712
    2025Q4Dec 31, 20255,60912
    2025Q3Sep 30, 20256,06311
    2025Q2Jun 30, 20256,28711
    2025Q1Mar 31, 20257,36210
    2024Q4Dec 31, 20248,38912
    2024Q3Sep 30, 20247,18511

    2026Q3 Earnings Call

    Opening remarks

    Eric Burns VP of Finance and Investor Relations Thank you, operator, and good morning, everyone. Joining me on today's call are Vericel's President and Chief Executive Officer, Nick Colangelo, and our Chief Financial Officer, Joe Mara. Before we begin, I would like to remind you that the discussions during this conference call will include forward-looking statements. Factors that could cause actual results to differ materially from expectations are discussed more fully in the company's most recent filings with the SEC. Also, the discussions today will include certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP financial measures can be found in today's press release, which is included as an exhibit to Vericel's current report on Form 8-K filed today with the SEC. A short presentation with highlights from today's call is also available in the Investor Relations section of our website. I will now turn the call over to Nick.

    Nick Colangelo President and Chief Executive Officer Thank you, Eric, and good morning, everyone. The company had an outstanding third quarter, which was the strongest quarter of the year on a number of measures for the company, MACI, and our burn care business, as we generated top-tier revenue growth across the portfolio, an inflection in profitability, and significant free cash flow. We delivered record third quarter total revenue of more than $85 million, which increased 26% over last year and significantly exceeded our guidance for the quarter. Based on our third quarter outperformance and the strong momentum that has continued into the fourth quarter, we are raising our full-year total revenue guidance to $344 million-$346 million, which represents 25% revenue growth for the year at the midpoint and an increase in revenue guidance of nearly $25 million since the start of the year. We also had another excellent quarter from a profitability perspective, as net income nearly tripled, adjusted EBITDA grew nearly 50% to more than $25 million, and adjusted EBITDA margin increased to 30%, which was significantly higher than our guidance for the quarter. Based on this outperformance on profitability measures, we are also raising our adjusted EBITDA margin guidance for the year. MACI had another great quarter with record third quarter revenue of more than $67 million, which exceeded our guidance for the quarter and increased 21% versus the prior year, marking the sixth consecutive quarter with MACI revenue growth of 20% or more, which was notable given the significant acceleration in MACI implant and revenue growth in the third quarter of last year. Beyond MACI's strong revenue performance, we continue to see significant momentum in the underlying business fundamentals that support sustained MACI growth. We achieved record third quarter MACI biopsies, implants, and biopsy and implanting surgeons.

    Frequently Asked Questions About VCEL

    When is Vericel Corp Ord's next earnings date?

    Vericel Corp Ord's next earnings report is expected for Feb 24, 2027.

    What EPS do analysts expect from VCEL next quarter?

    The consensus EPS estimate for Vericel Corp Ord for the quarter ending Dec 31, 2026 is $0.58 from 10 analysts, with estimates from $0.46 to $0.65.

    How often does VCEL beat earnings estimates?

    Vericel Corp Ord beat the EPS estimate in 5 of the 8 most recent quarters that had an estimate, with an average surprise of +38.42%.